Video Interview: Prothena Tackles Diseases Of Protein Accumulation
This article was originally published in Scrip
Executive Summary
Prothena President and CEO Dr. Dale Schenk briefs Mike Ward, global director of content of Informa's pharma insights portfolio, on the progress the company has made since it spun out of Elan Corp at the end of 2012. The Irish company has three antibody programs focusing on diseases associated with protein accumulation in the clinic. The lead program is NEOD001, which is a monoclonal antibody targeting the amyloid that accumulates in light chain amyloidosis. Dr. Schenk reveals that he expects to report results from the Phase IIb PRONTO trial at the end of 2017, early 2018, while the results of the pivotal Phase III VITAL study will come after that. In collaboration with Roche, the company is developing a monoclonal antibody, PRX002, that targets alpha-synuclein, a protein that has a fundamental role in the progression of Parkinson's disease and other conditions. Dr. Schenk reveals that the company has already completed one Phase I study with the molecule and is expecting to report the results of a much larger Phase I trial by the end of 2016. The third program is a monoclonal antibody, PRX003, that selectively blocks MCAM-mediated cell adhesion, which is in Phase I trials and is being developed as a treatment for psoriasis and other inflammatory conditions.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.